We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Durex redux

27 July 2021 By Dasha Afanasieva

The Strepsils maker’s stock fell as much as 9%, as rising costs hurt its profitability. The shares are now down since CEO Laxman Narasimhan took over in 2019, highlighting the challenges he faces in reviving the group’s fortunes. A likely boom in cold medicine sales should help.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)